Source Post

Psychedelic Stocks To Buy | Crash Over As Trump Approves Ibogaine

The creator discusses the potential resurgence of psychedelic stocks, citing recent White House reforms and executive orders aimed at accelerating the review and commercialization of psychedelic drug treatments. While acknowledging past successes with MindMed (now Definium Therapeutics) and the current phase three trials for both MindMed and Compass Pathways, the creator expresses significant caution due to the sector's historical volatility and the high failure rate of clinical trials. Despite holding a small, nostalgic position in MindMed, the creator advises against investing in the sector, highlighting massive losses experienced by other investors and the insufficient government funding allocated.